Hepatitis B, Chronic
Conditions
Brief summary
The study is a phase 2a, single blind, randomized, placebo controlled, study evaluating the safety, anti-viral activity, and pharmacokinetics (PK) following multiple doses of intravenous ARB-001467
Detailed description
Approximately 24 subjects will be enrolled in three cohorts: two cohorts of HBeAg-negative subjects and one cohort of HBeAg-positive subjects and 12 HbeAg-negative subjects will be enrolled in cohort 4. All subjects will be non-cirrhotic, with chronic hepatitis B virus (HBV) infection, and will have been receiving nucleos(t)ide-analogue (NA) therapy with entecavir or tenofovir for at least 12 months.
Interventions
DRUGARB-001467
An IV infusion of ARB-001467
OTHERPlacebo
An IV infusion of placebo
Sponsors
Arbutus Biopharma Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Masking description
Single Blind (Subject) in cohort 1-3, Open label in Cohort 4
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Documented chronic HBV infection for ≥12 months prior to Screening Visit. * Quantitative HBsAg ≥1000 IU/mL at the Screening Visit. * Subjects currently receiving entecavir and/or tenofovir for ≥12 months and HBV DNA undetectable. Key
Exclusion criteria
* Known co-infection with HIV, hepatitis C virus, and hepatitis D virus. * Receiving or planning to receive systemic immunosuppressive medications during the study or ≤2 months prior to the first dose of study treatment. * Receiving or planning to receive interferon during the study or ≤12 months prior to the first dose of study treatment. * Significant immunosuppression from, but not limited to immunodeficiency conditions such as common variable hypogammaglobulinemia. * Clinical diagnosis of substance abuse with alcohol, narcotics, or cocaine ≤12 months prior to the Screening Visit. * Any known pre-existing medical or psychiatric condition that could interfere with the subject's ability to provide informed consent or participate in study conduct, or that may confound study findings.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency and severity of treatment-emergent SAEs, discontinuations due to AEs, and laboratory abnormalities, by cohort, through 28 days after the last infusion of study treatment. | 28 days post last infusion | To evaluate the safety and tolerability of multiple doses of ARB-001467 in HBeAg-negative and HBeAg-positive subjects with chronic Hepatitis B virus infection who are receiving nucleos(t)ide analogue therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate ARB-001467 Maximum plasma concentration (Cmax) at multiple time points from baseline through Day 85; 28 days after the last infusion of study treatment (cohort 1-3) and Week 36 (Cohort 4). | Up to 36 Weeks | To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection. |
| Evaluate ARB-001467 Time to maximum plasma concentration (Tmax) at multiple time points from baseline through Day 85; 28 days after the last infusion of study treatment (cohort 1-3) and Week 36 (Cohort 4). | Up to 36 Weeks | To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection. |
| Evaluate ARB-001467 Area under the plasma concentration-time curve from the start of infusion to the last measurable concentration (AUC0-t) at multiple time points from baseline through Day 85 (cohort 1-3) and Week 36 (Cohort 4). | Up to 36 Weeks | To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection. |
| Evaluate additional parameters for ARB-001467 from plasma concentration-time curve from start of infusion and extrapolated to infinity (AUC0-t), inf) partial, AUCs, T1/2, volume of distribution (VD) and clearance (CL) -baseline through Day 85 or Week 36. | Up to 36 Weeks | To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection. |
| Evaluate antiviral activity of ARB 001467 for up to 72 weeks after the first dose of study treatment. | Up to 18 months | The proportion of subjects in each dose level cohort with ≥0.5 log10 HBsAg decrease from baseline at EOS, and for these subjects, the changes from baseline (expressed as percentage and log10 change) in the following virologic markers will be assessed throughout the study: * Quantitative HBV surface antigen (HBsAg) * Quantitative HBV surface antibody (HBsAb) * Quantitative HBV DNA and HBV-RNA (viral load) For the HBeAg positive cohort only: \- Quantitative HBV e antigen (HBeAg) |
Countries
Australia, New Zealand
Outcome results
None listed